₹2532.85 -49.3 -1.9%
Last Trade - 13/04/21
| Market Cap | £4.02bn |
| Enterprise Value | £3.87bn |
| Revenue | £377.4m |
| Position in Universe | 91st / 3106 |
| Industry | Market | |
|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
| Year End 31st Mar | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021E | 2022E | CAGR / Avg | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.000 | 0.000 | 0.000 | 16,229 | 20,442 | 26,332 | 34,027 | 40,141 | +27.4% | ||
| +33.5 | +63.3 | +28.6 | +22.9 | |||||||
|
x
|
||||||||||
| Profitability | ||||||||||
|
%
|
||||||||||
|
%
|
||||||||||
|
%
|
||||||||||
| Cashflow | ||||||||||
| Dividends | ||||||||||
| Balance Sheet | ||||||||||
|
m
|
||||||||||
|
m
|
||||||||||
|
m
|
||||||||||
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing % | |||
| Net Gearing % | |||
| Cash / Assets % |
| Liquidity (ttm) | ||
|---|---|---|
| Curr. Ratio | ||
| Quick Ratio | ||
| Interest Cov. | ||
| Efficiency (ttm) | ||
|---|---|---|
| Asset Turnover | ||
| Recs Turnover | ||
| Stock Turnover | ||
| Latest interim period vs. prior period | Industry | Market |
|---|---|---|
|
|
|
|
|
|
|
| 3yr Compound Annual Growth Rate | Industry | Market |
|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
Revenue
Net Income
Normalised EPS
PE Ratio Range
Dividend Yield Range
|
Price Target:
( below Price)
|
31st Dec 2021
|
31st Dec 2022
|
||||
|---|---|---|---|---|---|---|
| Est. Long Term Growth Rate: |
Net Profit () |
EPS () |
DPS () |
Net Profit () |
EPS () |
DPS () |
| Consensus Estimate | ||||||
| 1m Change | ||||||
| 3m Change | ||||||
Gland Pharma Limited is an India-based company that manufactures small volume parenterals (SVPs). The Company provides a range of injectables including vials, ampoules, pre-filled syringes, lyophilized vials, dry powders, infusions and ophthalmic solutions. It provides contract development and manufacturing services, such as evaluation of development needs, identifying application program interface (API) sources, analytical method development, formulation development and product / technology know-how; and manufacturing of registration batches, studies, dossier compilation for regulatory submission and commercial production. The Company’s therapeutic categories include Anti-Infectives, Anaesthetics, Anti-Coagulants and their Antidotes, Anti-Malarial, Cardiology, Gastro-Intestinal, Pain Management, Orthopaedics, Haematinics, Hormones and Related Drugs, Fertility Supplements, and Gnrh Agonists and Antagonists.
| Last Annual | March 31st, 2020 |
| Last Interim | December 31st, 2020 |
| Incorporated | March 20, 1978 |
| No. of Shareholders: | n/a |
| No. of Employees: | 3,766 |
| Sector | Healthcare |
| Industry | Pharmaceuticals |
| Index | |
| Exchange | National Stock Exchange of India |
| Shares in Issue | 163,592,923 |
| Free Float | (0.0%) |
| Eligible for |
✓
ISAs
✓
SIPPs
|
| Address | Survey No143-148150&151,Near Gandimaisamma 'X' Roads, DP Pally Dundigal Gandimaisamma Manda, HYDERABAD, 500043, India |
| Web | http://www.glandpharma.com/ |
| Phone | +91 40 30510999 |
| Contact | () |
| Auditors | S.R. BATLIBOI & ASSOCIATES LLP |
As of 13/04/21, shares in Gland Pharma are trading at ₹2532.85, giving the company a market capitalisation of £4.02bn. This share price information is delayed by 15 minutes.
Shares in Gland Pharma are currently trading at ₹2532.85 and the price has moved by % over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Gland Pharma price has moved by % over the past year.
There are no analysts currently covering Gland Pharma.
Gland Pharma is scheduled to issue upcoming financial results on the following dates:
Gland Pharma does not currently pay a dividend.
Gland Pharma does not currently pay a dividend.
Gland Pharma does not currently pay a dividend.
To buy shares in Gland Pharma you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
Shares in Gland Pharma are currently trading at ₹2532.85, giving the company a market capitalisation of £4.02bn.
Here are the trading details for Gland Pharma:
Based on an overall assessment of its quality, value and momentum, Gland Pharma is currently classified as a Falling Star. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Shares in Gland Pharma are currently priced at ₹2532.85. At that level they are trading at 2.62% discount to the analyst consensus target price of 0.00.
Analysts covering Gland Pharma currently have a consensus Earnings Per Share (EPS) forecast of 59.796 for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Gland Pharma. Over the past six months, the relative strength of its shares against the market has been %. At the current price of ₹2532.85, shares in Gland Pharma are trading at 8.46% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Gland Pharma PE ratio based on its reported earnings over the past 12 months is 35.1. The shares are currently trading at ₹2532.85.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Gland Pharma's management team is headed by:
Here are the top five shareholders of Gland Pharma based on the size of their shareholding:
